MAP3K5 and cardiac hypertrophy: Indeed, treatment with the ASK1 inhibitor selonsertib ameliorated AngII-induced cardiac hypertrophy and fibrosis in mice [71] and treatment with GS-459679, another ASK1 inhibitor, reduced infarct size and improved systolic function following I/R injury [103].